We are a precision oncology company pioneering the development of cancer therapies. Guided by Foresight, our proprietary functional genomics platform, we are deeply rooted in science and innovation with the vision to compassionately contribute to solving cancer.
Learn More
Fore was founded in 2011 as NovellusDx. We focus on people with genetically defined cancers, whose current treatment options are limited.
We are in the business of life. We aim to evolve the biotech model by harnessing the best of science and innovation, within and outside our walls. Our mission is to find and match the right therapies for the right patients with the hardest to treat cancers, and provide access in the most expeditious and high quality manner.
With our integrated functional genomics and machine learning drug discovery engine, we synthesize a wide range of mutations across validated oncological targets and in-license clinical stage small molecule assets to develop for hyper-targeted patient populations.
Our lead program, PLX-8394, a promising next generation treatment for Class I/II BRAF mutations, is an advanced investigational drug in Ph I/II trials, which was identified by our platform for its inhibitory effect across a wide range of unique BRAF mutations.
For more information, please see the following press release or download our corporate presentation.
Yaron Shimon, CPA
VP Finance & Operation
+972 (0) 25956597
yaron@fore.bio